Dosages
Side effects in children
Warnings & precautions in children
Contra-indications in children

Interactions
PK
Renal impairment
References

Varicellazostervaccine

Generic name
Varicellazostervaccine
Brand name
ATC Code
J07BK01

Pharmacokinetics in children

No information is present at this moment.

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

dose recommendation of formulary compared to licensed use (on-label versus off-label)

No information is present at this moment.

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

Available formulations

No information is present at this moment.

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

Dosages

Active immunization against varicella zoster
  • Intramuscular
    • 9 months up to 12 months
      [1]
      • 2 doses (at least 1350 pfu/dose) with an interval of at least 3 months.

    • 12 months up to 13 years
      [1]
      • 2 doses (at least 1350 pfu/dose) with an interval of at least 1 month

      • Children with an asymptomatic HIV infection (CDC class 1) and an age-specific CD4+ T-lymphocyte percentage > 25% must be given two doses, with an interval of 12 weeks.

    • ≥ 13 years
      [1]
      • 2 doses (at least 1350 pfu/dose) with an interval of at least 1-2 months

  • Subcutaneous
    • 9 months up to 12 months
      [1]
      • 2 doses (at least 1350 pfu/dose) with an interval of at least 3 months

    • 12 months up to 13 years
      [1]
      • 2 doses (at least 1350 pfu/dose) with an interval of at least 1 month

      • Children with an asymptomatic HIV infection (CDC class 1) and an age-specific CD4+ T-lymphocyte percentage > 25% must be given two doses, with an interval of 12 weeks.

    • ≥ 13 years
      [1]
      • 2 doses (at least 1350 pfu/dose) with an interval of at least 1-2 months

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

Renal impaiment in children > 3 months

No information available on dose adjustment in renal impairment.

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here

Side effects

No information is present at this moment.

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here

Contra-indications

No information available on specific contra indications in children.

The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here

Warnings & precautions in children

Live attenuated vaccines (e.g., varicella zoster vaccine) should not be given to infants exposed to infliximab in utero until 12 months after birth. Administration of a live attenuated vaccine to a breastfed infant while the mother is receiving infliximab is not recommended unless serum levels of infliximab are undetectable in the infant. These infants may be at increased risk of infection, including severe disseminated infection that can become fatal. [DHPC]

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

Interactions

The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

References

  1. Merck Sharp & Dohme BV, SmPC Provarivax (RVG 29215) 24-02-2017, www.geneesmiddeleninformatiebank.nl
  2. Representatives of marketing authorisation holders of infliximab, DHPC Infliximab 07 maart 2022,, https://www.cbg-meb.nl/documenten/brieven/2022/03/08/dhpc-infliximab

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

Changes

Changes